Extensive experimental application of bot ulinum toxin (BTX) has shown the drug to be without reported systemic toxicity in doses used in ophthalmology (Table I) . However, induced vertical strabismus and/or ptosis occur in 15 to 25% of horizontal extraocular muscle injections due to diffusion from the target muscle into adjacent muscles. This is especially true of the medial rectus, where combined weakness from overflow to the supradjacent superior oblique and subjacent inferior rectus, both depressor muscles, results in hypertropia. While local side effects are usually mild and transient, they limit dos age, interfere with securing binocularity during the period of drug-induced palsy, and create vertical strabismus of two prism diop ters or more at six months after injection in 1.8% of cases. In the eyelid, diffusion of the drug from the injected orbicularis muscle may involve both the levator, causing ptosis, and the superior rectus, causing vertical diplopia. This paper describes some experiments to limit or avoid these side effects using antitoxin (ATX). Timely use of antitoxin may be useful to avoid effects of erroneous BTX usage, too.
Methods and Results
We used botulism antitoxin ABE, Connaught Laboratories, containing about 750 inter national units (IV) of type A antitoxin of equine origin per milliliter. By convention each IV neutralises 10,000 mouse LD/50 doses of type A toxin. Botulinum toxin type A is expressed in units, each unit being equal to a mouse LD/50 dose and corresponds to about 0.36 nanograms of the crystalline toxin haemagglutin complex.
Orbicularis ATX following orbicularis

BTX
To study the ability of small local doses of ATX to inhibit BTX effect, eleven blepharospasm patients were injected with ATX in the right orbicularis immediately after receiving BTX injections of equal doses to both eyes. ATX doses ranged from 1.0 x 104 to 1.6 x 10-3 IV of ATX per BTX unit. This dosage range had been previously worked out in mouse experiments. An additional eleven patients received delayed ATX injections, with intervals between BTX and ATX injec tions ranging from � hour to 21 hours. Results were assessed by measuring the pre-and post injection orbicularis force in both eyes. When direct force measurements were unobtain able, a subjective assessment of the difference in spasm duration and intensity between the two eyes was obtained by telephone follow up. All responses were then graded on a scale of 0 to 3, where 0 = no ATX effect (response to BTX equal in both eyes) and 3 = marked ATX effect (orbicularis force/spasm intensity much greater in the ATX-treated eye, indicat ing inhibition of BTX effect). After the effect of ATX was assessed, patients who had a reduced BTX effect in the ATX-treated eye were retreated with BTX to that eye to give them the usual relief from spasm.
Results are shown in Table II and sum marised in Figure 1 . As expected, increasing ATX doses resulted in increasing blockage of BTX effect. An unexpected result was that delaying the ATX injection for up to 5 hours following BTX injection resulted in increased blockage of BTX effect. Delays of 16-21 hours showed a reduced ATX effect, but did Corre$pondence to: Smith-Kettlewell Eye Research Foundation, San Francisco, California, USA.
Supported by National Institutes of Health grants #EY06523 and EY06883. 
Levator or inferior rectus ATX following horizontal rectus BTX injection
Five strabismus patients received ATX injec tions: to the temporal side of the levator or inferior rectus following BTX injection to the medial rectus, and vice versa for the lateral rectus. (See Table IV ). Ptosis of 1 mm occurred in patient #815 and slight inferior rectus weakness occurred in patient #501.
The paralysis of the target muscle was com plete in all cases.
Reversal of established paralysis, even using high ATX doses, was not possible in patient #801. 
